M&T Bank Corp Sells 11,702 Shares of Solventum Co. (NYSE:SOLV)

M&T Bank Corp trimmed its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 22.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,607 shares of the company's stock after selling 11,702 shares during the period. M&T Bank Corp's holdings in Solventum were worth $2,761,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Worldquant Millennium Advisors LLC boosted its stake in shares of Solventum by 373.6% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company's stock valued at $3,323,000 after buying an additional 37,600 shares during the period. The Manufacturers Life Insurance Company grew its stake in Solventum by 37.4% in the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company's stock valued at $8,217,000 after purchasing an additional 32,051 shares in the last quarter. State Street Corp increased its position in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company's stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Solventum during the 3rd quarter worth about $50,948,000. Finally, First Horizon Advisors Inc. acquired a new stake in shares of Solventum during the 2nd quarter valued at about $58,000.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of research reports. Mizuho began coverage on Solventum in a report on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 price objective on the stock. BTIG Research began coverage on shares of Solventum in a research note on Thursday, September 5th. They set a "neutral" rating on the stock. Morgan Stanley lifted their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Wolfe Research assumed coverage on shares of Solventum in a research report on Thursday, September 26th. They set a "peer perform" rating on the stock. Finally, Stifel Nicolaus initiated coverage on Solventum in a report on Tuesday, October 8th. They set a "buy" rating and a $82.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, Solventum has an average rating of "Hold" and a consensus target price of $68.29.

Solventum Stock Down 0.6 %

Shares of NYSE:SOLV traded down $0.45 during midday trading on Friday, hitting $69.56. The company's stock had a trading volume of 637,853 shares, compared to its average volume of 1,641,854. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock's 50 day simple moving average is $70.91 and its 200 day simple moving average is $63.22.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.